Community

William S. Marth

,

William S. Marth became President and CEO of Albany Molecular Research, Inc. in January 2014, after briefly serving as the company’s nonexecutive Chairman. In 2013, Mr Marth served as a senior advisor to Teva Pharmaceuticals following his retirement in 2012 as President and Chief Executive Officer of Teva – Americas. Mr Marth is recognised as an industry leader with an unparalleled record of commercial success. He also served as the architect of the $6.8 billion Cephalon and $7.4 billion Barr Laboratories acquisitions and integrations. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb. Mr Marth earned his BSc in Pharmacy from the University of Illinois in 1977 and his MBA in 1989 from the Keller Graduate School of Management, DeVry University. He is a licensed pharmacist and is currently the Chairman of the Board of Directors of Sorrento Therapeutics, and a director at Galmed and the University of Illinois at Chicago College of Pharmacy (UIC).